Logotype for Odinwell

Odinwell (ODIN) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Odinwell

Q3 2026 earnings summary

17 Nov, 2026

Executive summary

  • Q3 focus shifted from product development toward commercialization, with novaQS veterinary launch targeted for Q4 2026 and two global wound-care actors evaluating the platform.

  • After quarter-end, one global wound-care actor provided a Letter of Intent and another began an additional evaluation collaboration; a new patent application was filed in November.

Financial highlights

  • Q3 2026 revenue was SEK 816k vs. SEK 988k YoY; operating loss was SEK 1.442m vs. SEK 1.501m, and net loss was SEK 1.442m vs. SEK 1.400m.

  • Q3 EPS was -SEK 0.02 vs. -SEK 0.04 YoY; 9M revenue was SEK 2.580m vs. SEK 3.079m, operating loss SEK 4.052m vs. SEK 4.971m, and net loss SEK 4.027m vs. SEK 4.807m.

  • 9M EPS was -SEK 0.05 vs. -SEK 0.12; cash and cash equivalents were SEK 2.957m at Sep. 30, 2026, vs. SEK 3.485m a year earlier.

Outlook and guidance

  • CE marking and launch of novaQS for the veterinary market remained targeted for Q4 2026; results from the horse study are expected to support product use and marketing.

  • Commercial focus is moving toward market entry, with further customer, distributor and strategic-partner discussions underway in Sweden and internationally.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Odinwell